Investors Business Daily

Investors Business Daily
Share

Investors Business Daily

 •  December 16

Invest in the disruptors. That's the advice from Wall Street, as giant biotech companies and the incumbents of Big Pharma are bracing to get crushed by more innovative — and cheaper — new drugs. What started in 2017 will continue in 2018, analysts say. Generic drug approvals are rising and interesting new medicines are starting to take market share...

Investors Business Daily

 •  October 27

Insys Therapeutics (INSY) faced the same woes as at least one other troubled opioid maker in the wake of the arrest of the company's founder, largest shareholder and board member John Kapoor, as the stock was halted Friday. Kapoor was charged Thursday with leading a nationwide conspiracy to profit by using bribes and fraud to illegally distribute a...

Investors Business Daily

 •  October 16

Exelixis (EXEL) popped early Monday after its drug, Cabometyx, proved effective in treating patients with a form of liver cancer known as hepatocellular carcinoma — prompting officials to end the Phase 3 trial early. Autoplay: On | OffThe biotech also reported the Food and Drug Administration granted Cabometyx priority review as a first treatment...

Investors Business Daily

 •  October 13

A split Food and Drug Administration committee voted Friday to recommend approval for Aerie Pharmaceuticals' (AERI) glaucoma drug Rhopressa — sending the company's stock yo-yoing after it was briefly halted in early trades. Autoplay: On | OffIn afternoon trading on the stock market today, Aerie popped as much as 5%, dipped as much as 3.4% and was...

Investors Business Daily

 •  October 11

Seattle Genetics (SGEN) launched to its highest point in four months Wednesday after announcing a series of cancer drug trials with Dow component Merck (MRK) and Japanese drugmaker Astellas Pharma. Autoplay: On | OffBy the closing bell on the stock market today, Seattle Genetics had surged 6.5% to finish at 61.47. Earlier, shares lifted 9.8% to a...

Investors Business Daily

 •  October 5

Acadia Pharmaceuticals (ACAD) briefly rallied, then dipped nearly 1% early Thursday, in the wake of its announcement that its dementia drug had gotten breakthrough designation just ahead of enrolling a Phase 3 trial. Autoplay: On | OffAcadia popped as much as 5.3%, touching a high last seen in June 2016, before falling 1.4%, near 38.60 by midday on...

Investors Business Daily

 •  October 3

What's got a tax address in Ireland, headquarters in New Jersey, a blockbuster drug on a Native American reservation, and new trouble in Washington? If you guessed Allergan (AGN), you're right. Last month, Allergan said it would transfer the rights to Restasis, a blockbuster treatment for chronic dry eye that had $1.49 billion in sales last year,...

Investors Business Daily

 •  September 22

AGN) is advancing a hepatitis drug into Phase 3 testing that likely won't get Food and Drug Administration approval, an analyst predicted Friday. Autoplay: On | OffBut Mizuho analyst Irina Koffler is still constructive on Allergan stock on which she has a buy rating and 267 price target. In midday trading on the stock market today, Allergan lifted...

Investors Business Daily

 •  September 21

Intercept Pharmaceuticals (ICPT) neared a four-year low Thursday after the U.S. Food and Drug Administration warned of liver damage and death associated with the company's drug, Ocaliva. Autoplay: On | OffLeerink analyst Joseph Schwartz questioned whether the FDA could require Intercept to include a black box warning on its label for Ocaliva....

Investors Business Daily

 •  September 15

Bristol-Myers Squibb (BMY) is teaming up with Halozyme (HALO) to test its immuno-oncology drugs as injections using Halozyme's technology, the drugmakers announced early Thursday. Autoplay: On | OffHalozyme will receive a $105 million upfront payment as well as future milestones and royalties. Bristol's Opdivo, one of its immuno-oncology drugs, is...